CMRI Unveils Scarless Endoscopic Bariatric Surgery

India Pharma Outlook Team | Thursday, 25 January 2024

 India Pharma Outlook Team

Although prevention is essential, treatment of obesity classes 2 to 3 defies traditional methods with a success rate of 1 in 100 and is not surgically feasible for everyone due to surgical complications. An alternative option is endoscopic bariatric surgery or sleeve gastroplasty, a non-surgical procedure that uses advanced endoscopic instruments. This will make the stomach smaller, change the appetite and bowel pattern and provide an excellent option for those who do not want surgery and want to lose weight in the fight against obesity, says senior consultant Sarfaraz Baig. They are said to be obese and Hernia Gastrointestinal Surgeon /AWR Surgery, Calcutta Medical Research Institute (CMRI), Kolkata.

Department of Finance  Dr. Baig says collaboration between the public and private sectors is essential in an epidemic—endoscopic bariatric surgery with a slightly larger endoscope with two channels for insertion into the stomach. Using state-of-the-art equipment, we offer minimally invasive surgery similar to open or laparoscopic surgery for intrauterine closure using needle holders, sutures, and seals.

Because the procedure is performed orally, patients are discharged the same day without abdominal trauma. Recovery is quick, and pain is minimal; some people may experience nausea and abdominal cramps for the first 3-4 days, but these will gradually disappear. Clinical trials have demonstrated significant weight loss and safety equal to or superior to laparoscopic bariatric surgery.

Developing weight loss interventions requires years of research, early testing, and overcoming misconceptions. In recent years, many clinical trials, including the most important clinical trials, such as Merit, have contributed to establishing a good safety profile for the practice. Diet and lifestyle changes and physical training are essential to any treatment protocol, but they only have limited effectiveness, so other methods are crucial. For patients affected by level 1, the availability of several drugs is considered, and the combination of anti-obesity medications is considered. 

© 2024 India Pharma Outlook. All Rights Reserved.